Whole-Heart Myocardial Blood Flow Quantification Using MRI

  • STATUS
    Recruiting
  • End date
    Jan 1, 2025
  • participants needed
    160
  • sponsor
    Cedars-Sinai Medical Center
Updated on 25 February 2022
perfusion imaging
ischemia
adenosine
coronary disease
arterial disease
regadenoson
myocardial perfusion imaging
Accepts healthy volunteers

Summary

This study hopes to provide significant technical improvement in a Myocardial Blood Flow (MBF) cardiac magnetic resonance (CMR) quantification technique to address challenges and technical limitations for MBF CMR. By developing and validating novel techniques to improve first-pass perfusion (FPP) cardiac MR, we propose to increase diagnostic accuracy by minimizing false positives and false negatives, allow for better evaluation and accurate quantification of total ischemic burden and reduce image and motion-induced artifacts.

The broad, long-term objective of the proposed project is to improve the prognosis of patients with myocardial ischemia caused by coronary artery disease (CAD) or coronary microvascular dysfunction (CMD).

Description

All subjects will receive cardiac MRI scans to diagnose CAD or CMD. MR perfusion scans will be performed twice per subject: once at rest, and once after administration of a pharmacologic stress agent. There will be a >15 minute delay between the two scans. A gadolinium-based contrast agent will be administered during each scan to allow measurement of myocardial blood flow. Once myocardial blood flow is quantified, the measurements will be compared to previous reference measurements (when available) from PET myocardial perfusion imaging in the CAD patient cohort and coronary reactivity testing (CRT) in the CMD patient cohort.

Details
Condition Coronary Artery Disease, Coronary Microvascular Disease
Treatment Myocardial Perfusion Cardiac MRI., Contrast, Pharmacologic Stress Agent
Clinical Study IdentifierNCT03064295
SponsorCedars-Sinai Medical Center
Last Modified on25 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

healthy male or female (18 or older) participants
male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD)
female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD)

Exclusion Criteria

MR imaging is contraindicated in persons with mechanically, magnetically, or electrically activated implants, such as cardiac pacemakers, neurostimulators, and infusion pumps
Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial, aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged
Patients who are pregnant, nursing, implanted with non MR-compatible intrauterine devices (IUD's)
Persons unable to tolerate MRI imaging secondary to an inability to lie supine or severe claustrophobia
Persons who are non-compliant with visit instructions, including inability to lie still, hold breath or follow procedure instructions
Persons whose renal function test does not meet CSMC standard of care MRI contrast protocol requirements (GFR <45ml/min)
Persons with stated allergy to animal dander
acute coronary syndrome or acute myocardial infarction or ongoing myocardial ischemia or ECG evidence of ongoing ischemia
patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support or prior/planned PCI or CABG
non-ischemic cardiomyopathy or more than moderate valvular disease
contraindication to stress agent (adenosine) including asthma or prior adverse reaction to adenosine
contraindications for gadolinium contrast
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note